Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

112.55 -0.97 (-0.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
This big pharma company's juicy dividend is looking even more attractive. 
Via The Motley Fool
Topics Earnings
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy. 
Via Benzinga
Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk
Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage. 
Via Benzinga
Breaking Down BioNTech: 12 Analysts Share Their Views
 
Via Benzinga
These Analysts Revise Their Forecasts On BioNTech After Q2 Results
 
Via Benzinga
BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push
Via Stocktwits
Earnings Scheduled For August 4, 2025
 
Via Benzinga
A Look Ahead: BioNTech's Earnings Forecast
 
Via Benzinga
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance. 
Via Benzinga
BioNTech SE (NASDAQ:BNTX) Q2 2025 Earnings: Revenue Surges 68.5%, Losses Narrower Than Expected
BioNTech Q2 2025 earnings beat revenue estimates with $255.99M, narrowing losses to -$1.57 EPS. Shares rose 2% pre-market as oncology pipeline advances. 
Via Chartmill
Topics Earnings
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Moderna's Key Patent Win Overshadowed By Gloomy Outlook
Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce. 
Via Benzinga
Topics Intellectual Property
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion
Bristol Myers beat Q2 sales expectations but cut its 2025 EPS forecast as strategic charges and legacy product declines weighed on earnings. 
Via Benzinga
Where Will Pfizer (PFE) Be in 5 Years?
The big drugmaker should be even bigger over the next five years despite facing a patent cliff. 
Via The Motley Fool
Topics Intellectual Property
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken... 
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Ryan Richardson to Step Down from the Management Board
From BioNTech SE
Via GlobeNewswire
Breaking Down BioNTech: 12 Analysts Share Their Views
 
Via Benzinga
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data. 
Via Benzinga
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute. 
Via Benzinga
Topics Intellectual Property
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
Ex-Pfizer Exec Pulled Into House Probe Over Alleged COVID Vaccine Delay Through 2020 Election
The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election. 
Via Stocktwits
Topics Government Law Enforcement
Expert Outlook: BioNTech Through The Eyes Of 11 Analysts
 
Via Benzinga
5 Stocks To Ride The German Market Rally
 
Via Benzinga
Accenture To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN)
From Brodsky & Smith LLC
Via GlobeNewswire
Market Monitor News June 13 (Oracle UP - Gamestop DOWN)
U.S. stocks edge higher as inflation cools, Oracle soars on AI growth, and markets brace for Israel-Iran conflict escalation. 
Via Chartmill
Topics Artificial Intelligence Economy
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.